Kamada Ltd (KMDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
45
About the Report
About the Report
Summary
Kamada Ltd (Kamada) is a biopharmaceutical company that develops, manufactures and markets specialty proteins, specific immunoglobulins and other prescription medicines. Its major products include pulmonary related medicines, immunoglobins, vaccines and critical care medicines. It also offers medicines for the treatment of cystic fibrosis, asthma, heamophilia, rabies, hepatitis B, and other indications. Kamada's pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes and lung transplantation indications. The company distributes its products through a network of distributors in Brazil, Israel, Russia, India and other countries in Eastern Europe, Latin America and Asia regions. Kamada is headquartered in Ness Ziona, Israel.
Kamada Ltd (KMDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Kamada Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kamada Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Brosh Capital Acquires 6.2% Stake in Kamada 11
Partnerships 12
Tetra Bio-Pharma to Enter into Agreement with Kamada 12
Kamada Enters into Agreement with Mount Sinai Acute GvHD International Consortium 13
Kamada Enters into Partnership with BGN Technologies 14
Kamada Expands Partnership with Massachusetts General Hospital 15
Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 16
Kamada Partners with myTomorrows 17
Equity Offering 18
Kamada Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Kamada Completes Public Offering Of Shares For USD 59 Million 20
Kamada Ltd-Key Competitors 21
Kamada Ltd-Key Employees 22
Kamada Ltd-Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Kamada announces financial results for second quarter and first six months of 2018 24
May 15, 2018: Kamada Reports Financial Results for First Quarter of 2018 26
Feb 07, 2018: Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017 28
Nov 13, 2017: Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017 30
Aug 01, 2017: Kamada Reports Financial Results for Second Quarter and First Six Months of 2017 32
Jul 27, 2017: Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017 34
May 16, 2017: Kamada Reports 2017 First Quarter Financial Results 35
Feb 06, 2017: Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016 37
Corporate Communications 39
Nov 10, 2017: Kamada Announces Nomination of Three New Members to its Board of Directors 39
Sep 18, 2017: Kamada Announces CFO Transition 40
Feb 08, 2017: Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors 41
Clinical Trials 42
May 24, 2017: Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference 42
Other Significant Developments 43
Aug 29, 2018: Kamada provides updated full-year 2018 revenue guidance 43
Aug 16, 2018: Kamada announces the end of the labor strike in the company's manufacturing facility; all employees returned to work 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Figure
List of Figures
Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Kamada Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kamada Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Brosh Capital Acquires 6.2% Stake in Kamada 11
Tetra Bio-Pharma to Enter into Agreement with Kamada 12
Kamada Enters into Agreement with Mount Sinai Acute GvHD International Consortium 13
Kamada Enters into Partnership with BGN Technologies 14
Kamada Expands Partnership with Massachusetts General Hospital 15
Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 16
Kamada Partners with myTomorrows 17
Kamada Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Kamada Completes Public Offering Of Shares For USD 59 Million 20
Kamada Ltd, Key Competitors 21
Kamada Ltd, Key Employees 22
Kamada Ltd, Other Locations 23
Kamada Ltd, Subsidiaries 23
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.